Guidelines on the diagnosis and management of Waldenström macroglobulinaemia
- 15 February 2014
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 165 (3), 316-333
- https://doi.org/10.1111/bjh.12760
Abstract
No abstract availableThis publication has 121 references indexed in Scilit:
- Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphomaBlood, 2011
- Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumabBlood, 2011
- Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based studyBlood, 2010
- Immune-Related and Inflammatory Conditions and Risk of Lymphoplasmacytic Lymphoma or Waldenstrom MacroglobulinemiaJNCI Journal of the National Cancer Institute, 2010
- Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow‐up of the Eastern Cooperative Oncology Group E3A98 trialBritish Journal of Haematology, 2009
- Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaBlood, 2009
- Thalidomide and rituximab in Waldenstrom macroglobulinemiaBlood, 2008
- Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in SwedenBlood, 2008
- Chronic Immune Stimulation and Subsequent Waldenström MacroglobulinemiaJAMA Internal Medicine, 2008
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003